Total cash and cash equivalents and short-term investments were $133.7M as of March 31 compared to $93.2M as of December 31, 2018. “Evolus is well capitalized, our sales team is hired and trained, our head-to-head clinical data versus BOTOX(R) is published and we are now on the brink of launching the first new 900kDa neurotoxin to enter the United States in nearly 30 years,” said David Moatazedi, president and CEO. “We have delivered on all major company milestones, within our stated timelines, and we now set our sights on our goal of achieving the number two market position within 24 months of launch.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.